Following the urging from advisory committee members, the US FDA appears to be changing gears in its position on adding immediate-release (IR) opioids to the Risk Evaluation and Mitigation Strategy (REMS) program, as well as mandatory education.
FDA said in an announcement that it intends to require a REMS for all forms of opioids, with the purpose...




